Stevens–Johnson syndrome following combination therapy with pembrolizumab and enfortumab vedotin in a patient with metastatic urothelial carcinoma: A rare but serious adverse event (IMAGE)

Impact Journals LLC

Stevens–Johnson syndrome following combination therapy with pembrolizumab and enfortumab vedotin in a patient with metastatic urothelial carcinoma: A rare but serious adverse event

Caption

Oncoscience is an open-access traditional journal with a special mission: freeing oncology from publication cost. It is free for the readers and the authors.

Credit

Copyright © 2026 Rapamycin Press LLC dba Impact Journals Impact Journals ® is a registered trademark of Rapamycin Press LLC

Usage Restrictions

With credit to the original source.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.